Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Propel Health Communications, a 2025 MM+M Agency 100 honoree, hired Christopher Thorn as SVP, creative director and Lauren ...

Dewpoint Therapeutics, a startup working in the once-buzzy field of biomolecular condensates, has laid off most of its staff.